AR059972A1 - Administracion intranasal o inhalacional de virosomas - Google Patents

Administracion intranasal o inhalacional de virosomas

Info

Publication number
AR059972A1
AR059972A1 ARP070101114A ARP070101114A AR059972A1 AR 059972 A1 AR059972 A1 AR 059972A1 AR P070101114 A ARP070101114 A AR P070101114A AR P070101114 A ARP070101114 A AR P070101114A AR 059972 A1 AR059972 A1 AR 059972A1
Authority
AR
Argentina
Prior art keywords
intranasal
influenza
composition
inhalational administration
virosomes
Prior art date
Application number
ARP070101114A
Other languages
English (en)
Inventor
Rheineck Leyssius Dorine H Van
Pieter J Schoen
Jozef J P Nauta
Alexander J Kersten
Lisya Gerez
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of AR059972A1 publication Critical patent/AR059972A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composicion de virosomas de influenza que comprenden envolturas reconstituidas de dicho virus, donde las envolturas virales están totalmente derivadas de partículas virales de influenza, donde no se agrega lípido de una fuente externa a los virosomas reconstituidos, donde los virosomas comprenden los antígenos de influenza hemoaglutinina y/o neuroaminidasa o derivados de los mismos, donde no se agrega adyuvante y/o estimulante inmune a la composicion y donde la composicion es para administracion intranasal o inhalacional, composicion que está caracterizada porque una sola administracion intranasal o inhalacional a un ser humano es suficiente para la induccion de una respuesta inmune sistémica y/o una respuesta inmune local y/o una respuesta de linfocitos citotoxicos contra dichos antígenos de influenza, respuesta sistémica que está en concordancia con los criterios CHMP (Comité para productos medicinales ara uso humano) para una vacuna de influenza y donde la dosis de hemoaglutinina por cepa viral por administracion intranasal o inhalacional es menor de o igual a 30 ?g. La invencion también provee el uso de virosomas de influenza reconstituidos para la fabricacion de dicha composicion y formulaciones de vacuna preparadas para dicho uso. Dispositivo para administracion intranasal o inhalacional.
ARP070101114A 2006-03-22 2007-03-20 Administracion intranasal o inhalacional de virosomas AR059972A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78446206P 2006-03-22 2006-03-22
EP06111534 2006-03-22

Publications (1)

Publication Number Publication Date
AR059972A1 true AR059972A1 (es) 2008-05-14

Family

ID=38038698

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101114A AR059972A1 (es) 2006-03-22 2007-03-20 Administracion intranasal o inhalacional de virosomas

Country Status (21)

Country Link
EP (2) EP2158921B1 (es)
JP (1) JP5285595B2 (es)
KR (1) KR20090016659A (es)
AR (1) AR059972A1 (es)
AT (2) ATE451931T1 (es)
AU (1) AU2007228736B2 (es)
BR (1) BRPI0709864A2 (es)
CA (1) CA2646895A1 (es)
DE (1) DE602007003815D1 (es)
DK (2) DK2158921T3 (es)
EA (1) EA014532B1 (es)
ES (2) ES2338382T3 (es)
HR (2) HRP20100144T1 (es)
IL (1) IL193840A (es)
MY (1) MY142996A (es)
NO (1) NO20084452L (es)
PL (2) PL2158921T3 (es)
PT (2) PT1996229E (es)
SA (1) SA07280116B1 (es)
SI (2) SI2158921T1 (es)
WO (1) WO2007107585A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2318044B1 (en) * 2008-08-01 2015-12-02 Gamma Vaccines Pty Limited Influenza vaccines
CA2826234A1 (en) * 2010-11-02 2012-05-10 Hector Manuel Zepeda Lopez Novel vaccines against the a/h1n1 pandemic flu virus
US11523988B2 (en) 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9018690D0 (en) * 1990-08-24 1990-10-10 Wellcome Found Vaccines
EP1447080A1 (en) * 2003-02-13 2004-08-18 Bestewil Holding B.V. Method for producing virosome-like particles
TWI329130B (en) * 2003-06-19 2010-08-21 Bestewil Holding Bv Functionally reconstituted viral membranes containing adjuvant

Also Published As

Publication number Publication date
EP1996229B1 (en) 2009-12-16
BRPI0709864A2 (pt) 2011-07-26
AU2007228736B2 (en) 2011-12-15
ES2375436T8 (es) 2012-03-15
DK1996229T3 (da) 2010-05-03
PL1996229T3 (pl) 2010-05-31
JP5285595B2 (ja) 2013-09-11
SA07280116B1 (ar) 2010-10-19
KR20090016659A (ko) 2009-02-17
EA200870361A1 (ru) 2009-02-27
CA2646895A1 (en) 2007-09-27
EP2158921B1 (en) 2012-01-04
ES2375436T3 (es) 2012-02-29
PL2158921T3 (pl) 2012-06-29
JP2009530351A (ja) 2009-08-27
HRP20120013T1 (hr) 2012-01-31
ES2338382T3 (es) 2010-05-06
EA014532B1 (ru) 2010-12-30
WO2007107585A1 (en) 2007-09-27
ATE539766T1 (de) 2012-01-15
HRP20100144T1 (hr) 2010-04-30
AU2007228736A1 (en) 2007-09-27
NO20084452L (no) 2008-10-22
MY142996A (en) 2011-02-14
SI1996229T1 (sl) 2010-04-30
ATE451931T1 (de) 2010-01-15
IL193840A (en) 2011-10-31
EP1996229A1 (en) 2008-12-03
IL193840A0 (en) 2011-08-01
DE602007003815D1 (en) 2010-01-28
PT2158921E (pt) 2012-03-27
SI2158921T1 (sl) 2012-03-30
DK2158921T3 (da) 2012-05-07
PT1996229E (pt) 2010-03-16
EP2158921A1 (en) 2010-03-03

Similar Documents

Publication Publication Date Title
CY1115308T1 (el) Συνθεσεις εμβολιου οι οποιες περιεχουν ανοσοενισχυτικο εκδοχο σαπωνινης
MX2010001054A (es) Composiciones adyuvantes antigenicas y metodos.
Geeraedts et al. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs
AR052625A1 (es) Nueva composicion
BRPI0510430A (pt) composições e métodos para vacinação mucosal
Baz et al. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice
CU23404A1 (es) Polisacáridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes
NO20005051L (no) Adjuvantsammensetninger
EA200900024A1 (ru) Противогриппозная вакцина
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
UY31285A1 (es) Vacunas
MXPA04001509A (es) Particulas de fosfato de calcio como coadyuvantes para la mucosa.
WO2014205199A3 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
CO6561819A2 (es) Vectores para vacunas y método para potenciar respuestas inmunes
BR112014011345A2 (pt) partículas tipo vírus da influenza (vlps) compreendendo nicotiana tabacum produzida por hemaglutinina
BR112015021523A2 (pt) composição de uma vacina contra a tosse convulsa acelular, e, métodos para vacinar um sujeito contra a bordetella pertussis e para proteger um sujeito da tosse convulsa
AR059972A1 (es) Administracion intranasal o inhalacional de virosomas
BRPI0606614A2 (pt) peptìdeos para distribuição de vacinas na mucosa
Cao et al. Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice
AR093530A1 (es) Adyuvante de vacunacion, preparacion, y vacunas que lo contienen
Altenburg et al. Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice
NZ583377A (en) Method of eliciting an immune response against pandemic influenza virus
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
BR112022007474A2 (pt) Vacina de partículas semelhantes a vírus chikungunya e métodos de uso da mesma
AR038311A1 (es) Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FA Abandonment or withdrawal